Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans
JH Oestreich, LG Best, PP Dobesh - American Heart Journal, 2014 - Elsevier
Background The prevalence of variant alleles of the CYP2C19 gene has been determined
for most population groups, but not Native Americans. Furthermore, the overall effectiveness …
for most population groups, but not Native Americans. Furthermore, the overall effectiveness …
Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
D Jones, S Persad-Ramdeensingh, SC Abrahim… - Cardiology and …, 2024 - Springer
Abstract Introduction Trinidad & Tobago has the highest prevalence of cardiovascular
disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used treatment. Yet, the …
disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used treatment. Yet, the …
Identification of CYP2C19* 4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness
SA Scott, S Martis, I Peter, Y Kasai… - The …, 2012 - nature.com
CYP2C19 is a principal enzyme involved in the bioactivation of the antiplatelet prodrug
clopidogrel and common CYP2C19 loss-of-function alleles are associated with adverse …
clopidogrel and common CYP2C19 loss-of-function alleles are associated with adverse …
Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
DL Bhatt - JAMA, 2009 - jamanetwork.com
ANTIPLATELET THERAPY HAS A PROMINENT ROLE IN THE treatment of a broad range of
cardiovascular dis-eases, and data supporting the role of aspirin in secondary prevention …
cardiovascular dis-eases, and data supporting the role of aspirin in secondary prevention …
CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
SA Mirabbasi, K Khalighi, Y Wu, S Walker… - Journal of community …, 2017 - Taylor & Francis
ABSTRACT Background: Clopidogrel (Plavix) is an antiplatelet medication that is routinely
used in patients with cardiovascular disease. Cytochrome P2C19 enzymes play a major role …
used in patients with cardiovascular disease. Cytochrome P2C19 enzymes play a major role …
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
Aims Clinical trials have established the value of clopidogrel therapy in a wide spectrum of
patients with cardiovascular diseases. Both loss-and gain-of-function single nucleotide …
patients with cardiovascular diseases. Both loss-and gain-of-function single nucleotide …
CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel
EF Magavern, B Jacobs, H Warren, G Finocchiaro… - JACC: Advances, 2023 - jacc.org
Background Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) is a hepatic
enzyme involved in the metabolism of clopidogrel from a prodrug to its active metabolite …
enzyme involved in the metabolism of clopidogrel from a prodrug to its active metabolite …
Impact of CYP2C19 metabolizer status on patients with ACS treated with prasugrel versus clopidogrel
JA Doll, ML Neely, MT Roe, PW Armstrong… - Journal of the American …, 2016 - jacc.org
Background Certain alleles of the CYP2C19 gene are associated with higher platelet
reactivity and increased ischemic events among patients treated with clopidogrel. However …
reactivity and increased ischemic events among patients treated with clopidogrel. However …
Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population
K Subraja, SA Dkhar, R Priyadharsini… - European journal of …, 2013 - Springer
Background The antiplatelet activity of clopidogrel is variable among patients suffering from
ischemic heart disease. Variation in the cytochrome P450 2C19 (CYP2C19) gene coding for …
ischemic heart disease. Variation in the cytochrome P450 2C19 (CYP2C19) gene coding for …
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
C Sukasem, R Tunthong, M Chamnanphon… - Pharmacogenomics …, 2013 - Taylor & Francis
Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented
gradually as the determinant conversion and variability in the antiplatelet effect of …
gradually as the determinant conversion and variability in the antiplatelet effect of …